

Presentation Khurram Sunasara

Leveraging mRNA Platform Technologies to Enable Pandemic Supply of COVID-19 Vx.

Abstract

This is a presentation describing the use of platform technologies to facilitate rapid development of a mRNA COVID-19 vaccine. This talk will emphasize the lessons learned and advantages of leveraging pDNA and mRNA platform technologies to rapidly expedite mRNA drug substance process development enabling pandemic supply of a COVID-19 mRNA Vaccine.

Speaker CV + photo



Khurram Sunasara is a group leader in Pfizer Inc.'s Bioprocess R&D group located in Saint Louis, MO where he leads a group of scientists involved in early and late stage downstream process and technology development focused primarily in the area of vaccine therapeutics. More recently, he has been responsible for co-leading the Pharmaceutical Science's COVID-19 mRNA vaccine drug substance team responsible for process development, scale-up, process characterization, regulatory filing and tech transfer of the mRNA DS process to commercial manufacturing. Khurram's 20+ years of industrial experience encompasses downstream development of several modalities including CHO and microbial expression systems such as *E.coli* and other native pathogens.